Tag: NSCLC

Clinical Trials Healthcare & Pharmaceuticals News

Lilly’s Retevmo Shows Substantial Survival Benefit in Early-Stage Lung Cancer Trial

Eli Lilly and Company

Eli Lilly’s Retevmo (selpercatinib) has shown promising results as an adjuvant therapy for early-stage lung cancer. The Phase 3 LIBRETTO-432 trial revealed that Retevmo adjuvant therapy significantly reduced the risk of disease recurrence or death in patients with RET fusion-positive non-small cell lung cancer (NSCLC), marking a breakthrough for this rare molecular subtype affecting 1-2% of lung cancer cases.

Regulatory Approval Healthcare & Pharmaceuticals News Oncology

Lilly’s Olomorasib Granted U.S. FDA Breakthrough Therapy Designation for Advanced Lung Cancer

Eli Lilly and Company

Eli Lilly announced its novel cancer drug, olomorasib, has been granted Breakthrough Therapy designation by the U.S. FDA. This significant milestone aims to expedite the development of the treatment for patients with advanced KRAS G12C-mutated non-small cell lung cancer, a historically difficult-to-treat condition.

Clinical Trials News Oncology

AstraZeneca’s Tagrisso with Chemotherapy Shows Significant Survival Benefit in Advanced Lung Cancer

AstraZeneca

AstraZeneca announced groundbreaking results from its FLAURA2 Phase III trial, revealing that Tagrisso (osimertinib) combined with chemotherapy offers a statistically significant and clinically meaningful improvement in overall survival for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC).